Department of Medicine, University of Toledo, USA
Mini Review
Personalized medicine and immunotherapy for ovarian cancer
Author(s): Stanbery Hannah*
The general prognosis for women with advanced ovarian cancer is still dismal,
despite advancements in surgery and chemotherapy. Although platinum-based
chemotherapy has an initial response rate of roughly 60–80%, the majority
of patients will have a recurrence and pass away from the disease. However, a
precision medicine approach focused on DNA repair has lately given rise to
genuine optimism about increasing survival. Many individuals with BRCA germlinedeficient
and/or platinum-sensitive epithelial ovarian malignancies have seen lifechanging
effects as a result of the clinical development of PARP inhibitors. Patients'
prognosis could also be improved by intraperitoneal chemotherapeutic methods
and antiangiogenic medications. Additionally, developing immunotherapeutic
possibilities could benefit patient results.
The effectiveness of immunother.. Read More»
